medigraphic.com
ISSN 1870-199X (Print)
Órgano oficial de la Facultad de Odontología, UNAM

2014, Number 2

<< Back Next >>

Rev Odont Mex 2014; 18 (2)

Chemotherapy-induced oral stomatotoxicity

Martínez GBL, Cruz RME, Echevarría PE

Language: Spanish
References: 39
Page: 89-95
PDF size: 235.75 Kb.


ABSTRACT

The principal aim of the present study was to determine the type of oral lesions most frequently found in breast cancer patients treated with chemotherapy at the General Hospital in Mexico City and establish under which circumstances these manifestations occur. A file review was undertaken, spanning from 1994 to 1999. Inclusion and exclusion criteria were established. Out of 405 cases under consideration, 327 cases were included in the sample. In these selected cases, stomatotoxicity was present in 129 cases: 89 cases exhibited only a single oral manifestation, 19 cases showed two and 14 cases exhibited more than two (three or more). Relationship between histological lineage was reflected; it was present in the infiltrating ducts, lobular and others (p ‹ .005). Treatment schemes with chemotherapy were integrated with 5-fluorouracil, adriamycin, cyclophosphamide and methrotrexate (p ‹ .005) dosage and stomatotoxicity were related (p ‹ .005).


REFERENCES

  1. López-Ríos O, Tovar-Guzmán V, Lazcano-Ponce E, Hernández-Ávila M. La epidemia de cáncer de mama en México ¿Consecuencias de la transición demográfica? Salud Pública. 1997; 39: 259-265.

  2. Boring C, Squires T, Tong T. Cancer around the world, 1986-1988. Cancer statistics. Cancer J. Clin. 1992; 42: 19-38.

  3. Atlanta American Cancer Society. Cancer facts and figures. 1991: 9.

  4. Dirección General de Estadística y Evaluación. Secretaría de Salud. Daños a la salud. Boletín de información estadística. 1992; 12.

  5. Peterson D, Sonis S. Oral complications of cancer chemotherapy. The Hague: Ed. Martinus Nijhoff Publishers; 1983. pp. 11-12.

  6. Wahlin YB, Matsson L. Oral mucosal lesions in patients with acute leukemia and related disorders during cytotoxic therapy. Scand J. Dent Res. 1988; 96 (2): 128-136.

  7. Hou GL, Tsai CC. Oral manifestations of agranulocytosis associated with methimazole therapy. J Periodontol. 1998; 59 (4): 244-248.

  8. Dreizen M. Oral complications of cancer therapies. Description and incidence of oral complication. NCI Monog. 1990; 9: 11-15.

  9. Simard-Savoie S. Oral manifestations in the patient taking antineoplastic medication. The role of the dentist. J. Dent Que. 1989; 26: 51-53.

  10. Carl W. Oral complications of local and systemic cancer treatment. Curr Opin Oncol. 1995; 7: 320-324.

  11. De Vita SH, Helman SA, Rosenberg S. Principles and practice of oncology. 5th edition. Philadelphia: Lippincott Williams & Wilkins; 1997. pp. 2705-2725.

  12. National Cancer Institute monographs. Consensus development conference on oral complications of cancer therapies: diagnosis, prevention and treatment. Bethesda: National Institutes of Health; 1990.

  13. Hernández-Muñoz GA. Avances en mastología. 2a. ed. Caracas Venezuela: Editorial Cromotip; 1990. pp. 147-155.

  14. Frykberg. Management of in situ and minimally invasive breast carcinoma. J. Surgery. 1994; 18: 45-57.

  15. Fernández-Ci et al. Anomalías del desarrollo mamario. En: Patología Mamaria. Barcelona: Salvat Editores; 1982. pp. 475-477.

  16. Cárdenas J. Primer Consenso Nacional sobre Tratamiento del Cáncer Mamario. Colima, México; Septiembre, 1994. Disponible en: http: //www.consensocancermamario.com/documentos/Folleto-Consenso-Nacional-1-Revision.pdf

  17. Simon AR, Roberts MW. Management of oral complications associated with cancer therapy in pediatric patients. Journal of Dentistry for Children. 1991; 58: 384-388.

  18. Peterson D, Sonis S. Oral complications of cancer chemotherapy. The Hague: Martins Nijhoff Publishing; 1983. pp. 113-149.

  19. Dreizen S. Oral complications of cancer therapies. Description and incidence of oral complications. NCI Monogr. 1990; 9: 11-15.

  20. Gordon B, Spadinger A, Hodges E, Ruby E, Stanley R, Coccia P. Effect of granulocyte macrophage colony stimulating factor on oral mucositis after hematopoietic stem cell transplantation. Journal of Clinical Oncology. 1994; 12 (9): 1917-1922.

  21. O’Sullivan E, Duggal MS, Bailey CC, Curzon MEJ. Changes in the oral microflora during cytotoxic chemotherapy in children being treated for acute leukemia. Oral Surgery, Oral Medicine, Oral Pathology. 1993; 76 (sppl. 2): 161-168.

  22. Bunetel L, Martine B, Rennes F. Oral pathoses caused by candida albicans during chemotherapy update on development mechanisms. Oral Surgery, Oral Medicine, Oral Pathology. 1996; 82 (2): 161-165.

  23. Chi KH, Chen CH, Chan WK, Chow KC, Chen SY, Yen SH et al. Effect of granulocyte-macrophage colony stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluoracil and leucovorin chemotherapy. Journal of Clinical Oncology. 1995; 13 (supl. 10): 2620-2628.

  24. Barash A, Peterson D, Tanzer J, D’ambrosio J, Nuk K, Schubet M et al. Helium-neon lasser affects on conditioning induced oral mucositis in bone marrow transplantation patients. Cancer. 1995; 76 (12): 2550-2556.

  25. Epstein J, Frances LWW. The efficacy of oral sucralfate suspention in prevention of oral mucositis due to radiation therapy. Int J Radiat Oncol Biol Phys. 1994; 28 (3): 693-698.

  26. Osaki T, Elisaku V, Kazunori Y, Josui H, Yetsuya Y. Prophylasis of oral mucositis associated with chemoradiotherapy of oral carcinoma by azelastine hydrochloride with other antioxidants. Head and neck. 1994; 16: 331-339.

  27. Fidler P, Loprizi Ch, Fallon J, Leitch J, Lee J, Hayes D et al. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU induced oral mucositis. Cancer. 1996; 77 (3): 522-525.

  28. Grandisher W. Docetaxel como tratamiento nedyuvante en pacientes con estadio III de cáncer de mama. Oncology. 1997; 8: 15-18.

  29. William CW Lawrence S. Management of oral mucositis during local radiation and systemic chemotherapy: A study of 98 patients. J. Prosthetic Dent. 1991; 66 (sppl 3): 361-369.

  30. Rosenberg S. Atención bucal de los pacientes bajo quimioterapia. “Care of the mouth”. Manual de Oncología. 1989. pp. 227-237.

  31. Peterson D. Oral toxicity of chemotherapeutic agents. Semin Oncol. 1992; 19 (5): 478-491.

  32. Overhoster CD, Peterson DE. Infection in acute nolynphocytic leukemia prevalence of acute exacervations. Arch Inter Med. 1982; 142: 51-54.

  33. Ramos de la RC. Manifestaciones orales en pacientes con carcinoma mamario bajo tratamiento de quimioterapia con esquemas a base de adriamicina [Tesis]. México: Hospital General de México; 1999. p. 20.

  34. Díaz-Rubio E. Monografías clínicas en oncología: efectos secundarias de la quimioterapia antineoplásica. Vol. II. Barcelona: S. A. Ediciones; 1990.

  35. Lockhart PB, Soriss T. Alterations in the oral mucosa caused by chemotherapeutic agents. J. Dental Surgery Oncology. 1981; 7: 15.

  36. Lynch M et al. Medicina bucal de Burkcet. 7a. ed. México: Ed. Mc Graw-Hill Interamericana; 1996.

  37. Scully C, Macfarlane TW. Orofacial manifestations of childhood malignancy: clinical and microbiological findings during remission. ASDJ Dent Child. 1983; 50: 121-125.

  38. Williams MC, Martin MV. A longitudinal study of the effects on the oral mucosa of treatment for acute childhood leukemia. Inter J Paed Dent.1992; 2: 73-79.

  39. Wimenga ANM, Vandergraff WTA, Spijkervet FLK, Times W, Tinner-Bosscha H, Slviter MJ et al. A new in vitro assay for cuantitation of chemotherapy induced mucositis. British Journal of Cancer. 1997; 76: 1062-1066.




2020     |     www.medigraphic.com